Articles tagged with Adjuvants
A new study published in The Lancet found that removing both pelvic and para-aortic lymph nodes significantly improves survival rates for patients with endometrial cancer who are at intermediate or high risk of cancer recurrence. The researchers concluded that this complete procedure should be recommended to these patients.
Researchers found that Herceptin significantly improved event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer, with a 3-year event-free survival rate of 71% compared to 56%. The treatment was well-tolerated, with only two patients experiencing symptomatic cardiac failure.
Researchers at Uppsala University have identified a biodegradable substance with higher activity than existing adjuvants, paving the way for therapeutic vaccines to be used as cost-effective treatments for diseases like cancer and allergies.
A phase 3 trial found that adding chemotherapy to tamoxifen treatment significantly improves disease-free survival in postmenopausal women with node-positive breast cancer. The benefit is maximized when tamoxifen follows chemotherapy.
Researchers found a statistically significant survival benefit from tamoxifen among premenopausal breast cancer patients with high ER-alpha S118-P expression. High ER-alpha S118-P levels were associated with improved recurrence-free survival compared to low expression levels.
Researchers at Fox Chase Cancer Center report an extremely low rate of acute dermatitis and cardiac toxicity when treating HER2-positive breast cancer patients with concurrent Trastuzumab and radiation therapy. The study suggests it may be safe to use both treatments in the adjuvant setting, pending longer follow-up.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded contracts to discover novel vaccine adjuvants. The goal is to enhance the immune response and extend vaccine supply. Researchers will test new compounds in animal models and human cells.
Researchers at Oregon State University have developed a new vaccine adjuvant using lecithin nanoparticles, which showed improved immune response and reduced toxicity compared to existing alum-based adjuvants. The new adjuvant could potentially become a universal carrier for vaccines and help tackle various diseases more effectively.
Countries are urged to prioritize post-marketing surveillance to address H1N1 vaccine safety concerns. The US is advised to support dose-sparing strategies to avoid depletion of the already short vaccine supply.
The report emphasizes the importance of identifying specific types of breast cancer and tailoring treatment to individual patients. It recommends adjuvant endocrine therapy for most patients with oestrogen receptor-positive tumours, anti-HER2 therapy for HER2-positive disease, and chemotherapy for triple-negative disease.
A tracking and feedback system reduced racial disparities in adjuvant therapy among women with early-stage breast cancer, increasing consultations with medical oncologists by 14 percentage points. The study found a decrease in underuse of adjuvant treatment, particularly among black and Hispanic women.
A novel intranasal influenza vaccine has elicited immune responses more than 20 times higher than traditional vaccines, using only half the standard antigen dose. The vaccine's nanoemulsion-based adjuvant system triggers unparalleled mucosal and systemic immunity without pro-inflammatory materials or cytokines.
Concomitant zoledronic acid prevents bone loss and improves bone-mineral density in premenopausal women with breast cancer during adjuvant endocrine therapy. After treatment, zoledronic acid even increases bone-mineral density.
A protein sequence associated with Huntington's disease has been identified as a potential life-saving vaccine component. The polyQ-based adjuvant efficiently enhances both branches of the immune response to a poor model antigen, with no apparent toxicity in mice.
Researchers found that alum stimulates clusters of proteins called inflammasomes, which respond to stresses such as infection or injury by releasing immune cell signaling proteins. This discovery provides evidence for the role of Nalp3 inflammasome in alum's adjuvant action.
A tracking system helped improve rates of medical oncology consultation and reduce disparities in breast cancer treatment by notifying surgeons when their patients visited an oncologist. The new system also eliminated racial disparity in treatment, as minority women were less likely to receive underuse of adjuvant therapy.
A study published in CANCER found racial differences in the use of breast cancer therapy among African-American and white women. African-Americans were less likely to receive adjuvant cancer therapy, while white women were more likely to take Tamoxifen and have chemotherapy.
A new study found that white women are almost five times more likely to take tamoxifen and three times more likely to have adjuvant chemotherapy for advanced breast cancer. Women with government health insurance were less likely to receive combination breast conserving surgery and radiation.
Two new studies found that switching to exemestane and adding trastuzumab improves disease-free survival and life expectancy in early breast cancer patients, at minimal additional cost. The treatments have been projected to save thousands of dollars per patient over their lifetime.
A recent survey found that three-quarters of women with breast cancer were not informed about their risk of recurrence, despite 96% relying on their healthcare provider for information. The study highlights the need for better communication between healthcare professionals and patients to ensure they receive life-saving information.
A study published in Immunology Letters describes new ways of inducing immune responses through selective B cell priming, suggesting a potential approach to rational vaccine design. This discovery could have significant practical implications for vaccination development.
A study by Ellen Peters found that numeracy significantly impacts how people process information, influencing decisions on medical options, stock investments, and risk assessment. The research highlights the importance of presentation in helping individuals better understand numbers and make informed choices.
Researchers have achieved effective immunity with a low dose of bird flu vaccine using MF59 adjuvant, potentially stretching vaccine supply. The study showed that antibody levels were significantly better and that a single dose of the adjuvanted vaccine was as good as two doses without adjuvant.
A new H5N1 influenza vaccine has produced a safe and effective immune response in healthy people at low doses, with the highest dose showing the best response. The vaccine was well-tolerated and did not have significantly more side effects compared to a placebo.
A two-dose regimen of the H5N1 vaccine induced the highest antibody response after 42 days, with all formulations well-tolerated. However, the level of post-vaccination antibodies needed for protection against the H5 N1 virus remains unknown.
A new study analyzed data from 3,193 stage III colon cancer patients and found that 78.2% completed adjuvant chemotherapy treatment. Incomplete treatment was linked to physical frailty, treatment complications, and lack of social support.
Women with hereditary non-BRCA breast cancer face a significantly higher risk of developing second primary breast cancers (CBCs), with probabilities ranging from 1.9% to 27.3% over 20 years. Adjuvant hormonal therapy can lower this risk, whereas chemotherapy has no apparent effect.
A large-scale analysis of stage I endometrial cancer patients reveals that adjuvant radiation therapy significantly improves overall and relative survival. Adjuvant RT shows particular benefits for patients with stage IC/grade 1 and grades 3 and 4 disease, resulting in lower death rates.
The use of chemotherapy after surgery for stage III colon cancer has increased, leading to improved 5-year survival rates. Adjuvant chemotherapy benefits younger and elderly patients equally, while black patients with high-grade cancers see less significant improvements.
Chemotherapy has been shown to improve survival rates for patients with advanced colon cancer, regardless of age or sex. The study found that women and the elderly received the same benefit as younger adults, but were less likely to receive chemotherapy treatment.
Researchers found that breast cancer death rates decreased by an estimated 25-38% due to the combination of screening and adjuvant therapy. The study used advanced statistical models to determine the contribution of each method, finding greater uncertainty with screening mammography estimates.
The HERA study found that Herceptin reduces the risk of cancer coming back by 52% and death by 33% in early-stage HER2-positive breast cancer. The results provide new hope for women with this aggressive form of breast cancer, offering improved survival rates.
Researchers have developed a new nasal vaccine that decreases Alzheimer's disease (AD) burden in mice by activating microglia to clear beta-amyloid from the brain. The vaccine combines an FDA-approved multiple sclerosis treatment, glatiramer acetate, with a safe and effective nasal adjuvant that has been tested in humans.
A meta-analysis of nine randomized trials found no significant difference in death rates or disease progression between neoadjuvant and adjuvant systemic therapy. However, neoadjuvant therapy was associated with a higher risk of loco-regional disease recurrence when radiation therapy was used without surgery.
A study presented at the SABCS showed a 30 percent reduction in breast cancer recurrence when postmenopausal women with hormone-receptor-positive breast cancer were switched from tamoxifen to AROMASIN after 2-3 years. This finding supports ASCO recommendations for adjuvant therapy with aromatase inhibitors.
A meta-analysis of RCT data found that patients receiving adjuvant chemotherapy had a lower risk of death and recurrence than those not receiving chemotherapy. Women with optimally staged stage I ovarian cancer may have an excellent prognosis without adjuvant chemotherapy.
The guideline states that routine adjuvant chemotherapy is not recommended for medically fit, average-risk patients with Stage II colon cancer. Patients who receive adjuvant chemotherapy have a small but significant benefit in survival rates, around 4-5% more chance of survival five years after surgery.
Researchers found that alum triggers the accumulation of Gr1 cells in the spleen, which prime B cells and facilitate their response to vaccines. The discovery sheds light on how adjuvants like alum enhance vaccine effectiveness.
Patients with stage I disease experienced longer intervals than those with more advanced disease. A multidisciplinary approach could help reduce anxiety and mistrust by allowing sufficient time for information digestion and procedure recovery.
A meta-analysis of five published trials found that aluminium-containing vaccines were more likely to cause redness and induration in young children and local pain in older children. However, there was no evidence of serious or long-lasting side effects.
A new study suggests that premenopausal women with ER-negative breast cancer may benefit from adjuvant chemotherapy alone or followed by goserelin, while those with ER-positive tumors show no significant difference in outcomes. The findings support the idea of ovarian suppression as a treatment alternative for some premenopausal women.
A new study published in the Journal of Clinical Oncology found that low-dose interferon therapy did not extend overall or recurrence-free survival in high-risk melanoma patients. The trial involved 674 patients and found that both groups experienced similar rates of disease recurrence and mortality.
A new study found that adjuvant chemotherapy did not improve survival rates for patients with surgically removed non-small-cell lung cancer. Additionally, a study on selenium supplementation revealed that it may increase the risk of squamous cell carcinoma and total nonmelanoma skin cancer in individuals at high risk.
A meta-analysis of 14 trials showed no survival benefit with chemotherapy, but adjuvant radiotherapy resulted in a 7% higher mortality rate. Professor Thatcher suggests further research is needed to confirm the result.
A new trial found a significant survival benefit from adjuvant chemotherapy in non-small cell lung cancer, increasing patient lifespan by 4.1%. The study suggests that toxicity is still a major concern and calls for better tools to identify patients who will benefit from treatment.
A decision aid called Decision Board improved patients' understanding of their disease, risk of recurrence, and treatment options. Women who used the board were more satisfied with decision making and preferred a more active role in their care.
High levels of AIB1 expression in breast cancer tumors are associated with poorer tamoxifen treatment outcomes. Patients with both high AIB1 and HER-2 expression have significantly worse disease-free survival compared to other patient groups.
The study found a significant discrepancy between recommended adjuvant chemotherapy and actual use, with younger women more likely to receive treatment. Overall, only 29% of women received chemotherapy, highlighting the need for re-evaluation of current NIH guidelines.
Two trials found that adjuvant chemotherapy improved recurrence-free survival by 8-11% and overall survival by 5-9%, primarily benefiting patients with unrecognized residual disease. These findings suggest that adjuvant chemotherapy may be most effective in patients with non-optimal surgical staging.
Researchers at Virginia Tech will develop plant-expressed antigens and adjuvants to create affordable, effective vaccines. The goal is to produce inexpensive, disease-fighting vaccines through plant-based delivery systems.
A follow-up study of 763 long-term breast cancer survivors found they maintain high levels of health, physical functioning, and emotional well-being. Social support was a significant predictor of current quality of life.
A study published in The New England Journal of Medicine reveals that weight gain and chemotherapy-induced ovarian failure are common problems among younger women with early-stage breast cancer. Researchers emphasize the importance of monitoring bone density and taking calcium supplements to mitigate potential long-term side effects.